Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

Yi Wen Huang, Albert Qin, Chan Yen Tsai, Pei Jer Chen

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis. It has a favorable pharmacokinetic profile and less frequent dosing schedule, i.e., once every two to four weeks, compared to conventional pegylated interferon products, which have multiple isomers and are administered weekly. It was approved for the long-term treatment of polycythemia vera, an MPN, and has been included in the NCCN clinical practice guidelines for this indication. Ropeginterferon alfa-2b has demonstrated efficacy and showed a favorable safety profile for the treatment of chronic viral hepatitis in several clinical studies. In this article, we review its pharmacokinetics and available clinical data and suggest that ropeginterferon alfa-2b administered once every two weeks can serve as a new treatment option for patients with chronic viral hepatitis, including chronic hepatitis B, C, and D.

Original languageEnglish
Article number1128
Issue number6
Publication statusPublished - Jun 2022


  • chronic hepatitis B
  • chronic hepatitis C
  • chronic hepatitis D
  • clinical trial
  • interferon
  • ropeginterferon alfa-2b

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology


Dive into the research topics of 'Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis'. Together they form a unique fingerprint.

Cite this